The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...

Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among ...

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all ...

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2 ...

CHICAGO -- Neoadjuvant chemotherapy failed to match upfront surgery for survival in resectable pancreatic cancer, a small randomized trial showed. Unexpectedly, patients assigned to surgery first ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified FOLFIRINOX ...

Researchers find that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer patients BUSAN, South Korea, Nov. 28, 2025 /PRNewswire/ -- A new ...